189 related articles for article (PubMed ID: 24249801)
1. Achieving consensus for clinical trials: the REiNS International Collaboration.
Plotkin SR; Blakeley JO; Dombi E; Fisher MJ; Hanemann CO; Walsh KS; Wolters PL; Widemann BC
Neurology; 2013 Nov; 81(21 Suppl 1):S1-5. PubMed ID: 24249801
[TBL] [Abstract][Full Text] [Related]
2. Conclusions and future directions for the REiNS International Collaboration.
Widemann BC; Blakeley JO; Dombi E; Fisher MJ; Hanemann CO; Walsh KS; Wolters PL; Plotkin SR
Neurology; 2013 Nov; 81(21 Suppl 1):S41-4. PubMed ID: 24249805
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.
Wolters PL; Martin S; Merker VL; Gardner KL; Hingtgen CM; Tonsgard JH; Schorry EK; Baldwin A;
Neurology; 2013 Nov; 81(21 Suppl 1):S6-14. PubMed ID: 24249806
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for imaging tumor response in neurofibromatosis clinical trials.
Dombi E; Ardern-Holmes SL; Babovic-Vuksanovic D; Barker FG; Connor S; Evans DG; Fisher MJ; Goutagny S; Harris GJ; Jaramillo D; Karajannis MA; Korf BR; Mautner V; Plotkin SR; Poussaint TY; Robertson K; Shih CS; Widemann BC;
Neurology; 2013 Nov; 81(21 Suppl 1):S33-40. PubMed ID: 24249804
[TBL] [Abstract][Full Text] [Related]
5. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
Ahlawat S; Fayad LM; Khan MS; Bredella MA; Harris GJ; Evans DG; Farschtschi S; Jacobs MA; Chhabra A; Salamon JM; Wenzel R; Mautner VF; Dombi E; Cai W; Plotkin SR; Blakeley JO; ;
Neurology; 2016 Aug; 87(7 Suppl 1):S31-9. PubMed ID: 27527647
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials.
Wolters PL; Martin S; Merker VL; Tonsgard JH; Solomon SE; Baldwin A; Bergner AL; Walsh K; Thompson HL; Gardner KL; Hingtgen CM; Schorry E; Dudley WN; Franklin B;
Neurology; 2016 Aug; 87(7 Suppl 1):S4-S12. PubMed ID: 27527648
[TBL] [Abstract][Full Text] [Related]
7. Lessons learned from drug trials in neurofibromatosis: A systematic review.
Dhaenens BAE; Ferner RE; Evans DG; Heimann G; Potratz C; van de Ketterij E; Kaindl AM; Hissink G; Carton C; Bakker A; Nievo M; Legius E; Oostenbrink R
Eur J Med Genet; 2021 Sep; 64(9):104281. PubMed ID: 34237445
[TBL] [Abstract][Full Text] [Related]
8. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
[TBL] [Abstract][Full Text] [Related]
9. Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration.
Merker VL; Gross AM; Widemann BC; Plotkin SR
Clin Trials; 2024 Feb; 21(1):3-5. PubMed ID: 37776044
[No Abstract] [Full Text] [Related]
10. Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.
Wolters PL; Vranceanu AM; Thompson HL; Martin S; Merker VL; Baldwin A; Barnett C; Koetsier KS; Hingtgen CM; Funes CJ; Tonsgard JH; Schorry EK; Allen T; Smith T; Franklin B; Reeve S;
Neurology; 2021 Aug; 97(7 Suppl 1):S50-S63. PubMed ID: 34230198
[TBL] [Abstract][Full Text] [Related]
11. Neurofibromatosis as a gateway to better treatment for a variety of malignancies.
Bakker AC; La Rosa S; Sherman LS; Knight P; Lee H; Pancza P; Nievo M
Prog Neurobiol; 2017 May; 152():149-165. PubMed ID: 26854064
[TBL] [Abstract][Full Text] [Related]
12. Identifying challenges in neurofibromatosis: a modified Delphi procedure.
Dhaenens BAE; Ferner RE; Bakker A; Nievo M; Evans DG; Wolkenstein P; Potratz C; Plotkin SR; Heimann G; Legius E; Oostenbrink R
Eur J Hum Genet; 2021 Nov; 29(11):1625-1633. PubMed ID: 33903738
[TBL] [Abstract][Full Text] [Related]
13. Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention.
Walsh KS; Janusz J; Wolters PL; Martin S; Klein-Tasman BP; Toledo-Tamula MA; Thompson HL; Payne JM; Hardy KK; de Blank P; Semerjian C; Gray LS; Solomon SE; Ullrich N;
Neurology; 2016 Aug; 87(7 Suppl 1):S21-30. PubMed ID: 27527646
[TBL] [Abstract][Full Text] [Related]
14. Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS.
Merker VL; Lessing AJ; Moss I; Hussey M; Oberlander B; Rose T; Thalheimer R; Wirtanen T; Wolters PL; Gross AM; Plotkin SR;
Neurology; 2021 Aug; 97(7 Suppl 1):S4-S14. PubMed ID: 34230208
[TBL] [Abstract][Full Text] [Related]
15. Patient Report of Hearing in Neurofibromatosis Type 2: Recommendations for Clinical Trials.
Thompson HL; Blanton A; Franklin B; Merker VL; Franck KH; Welling DB;
Neurology; 2021 Aug; 97(7 Suppl 1):S64-S72. PubMed ID: 34230203
[TBL] [Abstract][Full Text] [Related]
16. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
17. Current status and recommendations for biomarkers and biobanking in neurofibromatosis.
Hanemann CO; Blakeley JO; Nunes FP; Robertson K; Stemmer-Rachamimov A; Mautner V; Kurtz A; Ferguson M; Widemann BC; Evans DG; Ferner R; Carroll SL; Korf B; Wolkenstein P; Knight P; Plotkin SR;
Neurology; 2016 Aug; 87(7 Suppl 1):S40-8. PubMed ID: 27527649
[TBL] [Abstract][Full Text] [Related]
18. Back to the future: proceedings from the 2010 NF Conference.
Huson SM; Acosta MT; Belzberg AJ; Bernards A; Chernoff J; Cichowski K; Gareth Evans D; Ferner RE; Giovannini M; Korf BR; Listernick R; North KN; Packer RJ; Parada LF; Peltonen J; Ramesh V; Reilly KM; Risner JW; Schorry EK; Upadhyaya M; Viskochil DH; Zhu Y; Hunter-Schaedle K; Giancotti FG
Am J Med Genet A; 2011 Feb; 155A(2):307-21. PubMed ID: 21271647
[TBL] [Abstract][Full Text] [Related]
19. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
Tamura R
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574
[TBL] [Abstract][Full Text] [Related]
20. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
